drugset / Trial / NCT05524168
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
Phase 2
Active not recruiting
41 enrolled
Sun Yat-sen University
Chongqing University Cancer Hospital · collabFirst People's Hospital of Foshan · collabJiangxi Provincial Cancer Hospital · collabShenzhen People's Hospital · collabThe First Affiliated Hospital of Xiamen University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT combined with programmed death 1 (PD-1) antibody and chemotherapy in nasopharyngeal carcinoma patients with oligometastasis.
Timeline
- Start
- 2022-11-25
- Primary completion
- 2025-06-06
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |